Nosis Biological Sciences, Inc.

In silico peptide design platform

Co-founded in late 2021 by Jim Martineau, Seth Myers and Tim Craven, Nosis is advancing an in silico, deep learning design platform to solve drug delivery challenges with de novo cell-targeting peptides. The in silico peptide design platform empowers a novel multiplexed lab workflow that can test the entire extracellular receptor proteome simultaneously while recording multiple outcomes including binding, endocytosis, and endosomal escape. The method is not limited by peptide length thereby expanding the ultimate design space.